Globyz Biopharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Globyz Biopharma Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $32.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Globyz Biopharma Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $32.2K Trade | TransData Nexus

Globyz Biopharma Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $32.2K Total Trade · DGFT Verified

Globyz Biopharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $32.2K across 2 products in 1 therapeutic categories. Based on 11 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Osimertinib ($19.5K), Olaparib ($12.7K), .

Globyz Biopharma Private Limited — Export Portfolio & Destination Treemap

Globyz Biopharma Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Globyz Biopharma Private Limited? — Company Overview & Market Position

Globyz Biopharma Private Limited, established on June 1, 2015, is a private limited company headquartered in Raigarh, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH2015PTC265090 with the Registrar of Companies, Mumbai. It operates in the pharmaceutical sector, focusing on the manufacturing and export of finished pharmaceutical formulations. The authorized and paid-up capital of the company is ₹0.10 million each.

As of the latest available data, the company's revenue and employee count are not publicly disclosed. The registered office is located at Gala No 02 Shir Dhar Dahivali Karjat, Raigarh, Maharashtra, 410201.

What Does Globyz Biopharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Osimertinib$19.5K 2Olaparib$12.7K

Product Portfolio — Top 2 by Export Value

Globyz Biopharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Osimertinib	Advanced Oncology	$19.5K	5	1.8%	8
2	Olaparib	Advanced Oncology	$12.7K	6	1.4%	9

Globyz Biopharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $32.2K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Globyz Biopharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding the manufacturing facilities of Globyz Biopharma Private Limited, including plant locations, capacities, and specializations, are not publicly available. The company's registered address suggests operations in the Raigarh region of Maharashtra, but further information on manufacturing capabilities is not disclosed.

3Key Leadership

The current directors of Globyz Biopharma Private Limited are:

Mohsina Tanweer Ahmed Sonde
Abdul Rahman Hafiz
Mohammed Taha Tanweer Ahmed Sonde

Mohsina Tanweer Ahmed Sonde has been associated with the company since August 21, 2018. Abdul Rahman Hafiz joined on March 3, 2023, and Mohammed Taha Tanweer Ahmed Sonde on January 3, 2025.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Globyz Biopharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Globyz Biopharma Private Limited's export data indicates shipments to markets such as the United States, Jamaica, and India. However, specific regulatory filings, approvals, and market access statuses in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's export activities primarily focus on finished pharmaceutical formulations, including Osimertinib and Olaparib, within the Advanced Oncology therapeutic category.

2Emerging Markets

The company's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, and Southeast Asia. Additionally, there is no publicly available information on WHO prequalification status or other certifications that would enable access to these markets.

3Geographic Strategy

Globyz Biopharma Private Limited's export activities, as indicated by the available data, are concentrated in the Advanced Oncology therapeutic category, with Osimertinib and Olaparib as its primary products. The company's export value of $32,000 USD across 11 shipments suggests a focused approach, potentially indicating a strategy to establish a niche presence in specific markets. However, the limited diversification in product offerings and geographic reach may expose the company to concentration risks. A more diversified portfolio and expanded market presence could mitigate these risks and support sustainable growth.

Globyz Biopharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Globyz Biopharma Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not indicate FDA-approved products, and there is no disclosed information on its interactions with the FDA. This lack of FDA approvals may limit the company's ability to access the US market, which is a significant consideration for pharmaceutical exporters.

2WHO & EU GMP

There is no publicly available information regarding Globyz Biopharma Private Limited's WHO prequalification status or EU Good Manufacturing Practice (GMP) certifications. These certifications are crucial for accessing international markets and ensuring product quality and safety. The absence of such certifications may restrict the company's ability to expand its market reach and could impact its competitiveness in the global pharmaceutical industry.

3CDSCO & Indian Regulatory

Globyz Biopharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Globyz Biopharma Private Limited operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations in the Advanced Oncology therapeutic category. While specific competitors are not identified in the available data, the company's limited product portfolio and export value suggest that it may face competition from both large multinational pharmaceutical companies and other specialized exporters. The company's market share of 1.8% for Osimertinib and 1.4% for Olaparib indicates a modest presence in the global market. To enhance its competitive position, the company may consider diversifying its product offerings and expanding its market reach.

2Key Differentiators

Globyz Biopharma Private Limited's focus on finished pharmaceutical formulations, particularly in the Advanced Oncology therapeutic category, positions it as a specialized exporter in this niche market. The company's export data indicates a concentrated product portfolio, which may allow for expertise and quality assurance in its offerings. However, the limited diversification in products and markets may also pose challenges in terms of growth and risk management.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Globyz Biopharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Globyz Biopharma Private Limited's export data indicates a total export value of $32,000 USD across 11 shipments, with a portfolio concentration of 100% in the Advanced Oncology therapeutic category. The company's primary products, Osimertinib and Olaparib, have market shares of 1.8% and 1.4%, respectively. While the company demonstrates reliability in its export activities, the limited diversification in products and markets may affect its long-term sustainability and growth prospects.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. This can be verified through the FDA's official website or by contacting the FDA directly.

WHO Prequalification: Check if the products are prequalified by the World Health Organization (WHO), which is essential for accessing certain international markets. Verification can be done through the WHO's official website.

Frequently Asked Questions — Globyz Biopharma Private Limited

How many pharmaceutical products does Globyz Biopharma Private Limited export from India?

Globyz Biopharma Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Osimertinib ($19.5K), Olaparib ($12.7K). Total export value is $32.2K.

What is Globyz Biopharma Private Limited's total pharmaceutical export value?

Globyz Biopharma Private Limited's total pharmaceutical export value is $32.2K, based on 11 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Globyz Biopharma Private Limited cover?

Globyz Biopharma Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full Globyz Biopharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.